Sensus Healthcare NASDAQ: SRTS reported lower third-quarter revenue despite shipping more superficial radiation therapy systems, as product mix and the absence of sales to its historically largest customer weighed on the top line.
Sensus Healthcare, Inc. (SRTS) Q3 2026 Earnings Call Transcript
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September 30, 2026. Highlights included: Revenues of $6.0 million compared with $6.9 million in the third quarter of 2025, reflecting a product mix of lower-priced SRT-100 systems and the absence.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the sale of its 1,000th superficial radiotherapy (SRT) system, representing an important achievement in the Company's commercial development. This sale underscores Sensus' continued efforts to expand access to SRT as a non-invasive treatment option for non-melanoma.
UFP Technologies (NASDAQ: UFPT - Get Free Report) and Sensus Healthcare (NASDAQ: SRTS - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Analyst Recommendations This is a breakdown of current
Sensus Healthcare, Inc. (NASDAQ: SRTS - Get Free Report) has received an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating
Sensus Healthcare (NASDAQ: SRTS - Get Free Report) and STAAR Surgical (NASDAQ: STAA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations. Analyst Ratings This is a breakdown of
Sensus Healthcare NASDAQ: SRTS reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June.
Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un.